Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)



Status:Not yet recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:45 - 75
Updated:9/30/2018
Start Date:October 31, 2018
End Date:October 31, 2033
Contact:Irene Ghobrial, MD
Email:Irene_Ghobrial@dfci.harvard.edu
Phone:617-632-4198

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The PROMISE Study aims to establish a prospective cohort of individuals with precursor
conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance
(MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to
identify risk factors for progression to symptomatic multiple myeloma.

The goal of the PROMISE research study is to determine clinical/genomic alterations present
in individuals with MGUS and SMM, who are diagnosed though screening of a high-risk
population. We also seek to determine clinical/genomic/epigenetic and immune environmental
predictors of progression to multiple myeloma in patients with MGUS and SMM.

Inclusion Criteria:

- Age ≥ 45 and ≤75

- AA race (self-identified) and/or first-degree relative of a patient with plasma cell
dyscrasia such as MGUS, SMM, multiple myeloma, and Waldenström Macroglobulinemia

Exclusion Criteria:

-Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic
disease requiring active therapy
We found this trial at
1
site
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Irene Ghobrial, MD
Phone: 617-632-4198
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials